Fulgent Genetics, Inc.

NASDAQ:FLGT

Medical - Diagnostics & Research

Healthcare
$25.13 +1.89%

+$0.33 today

Market cap
$702.11M
Beta
0.92
P/E (TTM)
-7.5
EPS (TTM)
-$2.39
52W Low $13.46High $31.04

Volume 0.39M

Average 0.55M

FLGT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Fulgent Genetics, Inc.NASDAQ: FLGT

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures growth accelerates

Q1 FY2026 capital expenditures of $5.2M (cash outflow) rose 10.3% year over year, ahead of the -43.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.

Context

  • Capital expenditures amounted to 7.0% of revenue in FY2025, down 7.2 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +10.3% holds above the trailing-twelve-month pace of -43.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.2M+4.5% QoQ
Last fiscal yearDec 2025
-$22.57M-44.0% YoY
LTMMar 2026
-$23.06M-43.7% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.3%——
1 year-44.0%——
3-year CAGR+6.3%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(22.57M) USD
Year-over-year change
+44.0%

Capital Expenditures vs competitors

How FLGT compares with its peers on the latest reported figures

  • FLGT's LTM Mar 2026 capital expenditures of $23.06M is the 6th largest of the 8 companies compared; the peer median is $27.09M.
  • Its year-over-year change of -43.7% is the lowest of 7, against a peer median of +39.2%.
  • Capital expenditures amounts to 7.2% of revenue for FLGT, versus a peer median of 4.6%.
FLGT Competitors Peer median
Capital Expenditures for FLGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$156.54M +90.6%+30.6%5.8%
GHGuardant Health, Inc.LTM Sep 2026$58.67M +49.2%-14.6%4.6%
NEONeoGenomics, Inc.LTM Jun 2026$29.4M -11.5%-4.4%3.8%
WGSGeneDx Holdings Corp.LTM Jun 2026$27.09M +122.1%+9.9%6.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$23.2M -21.1%-29.9%2.8%
FLGTFulgent Genetics, Inc.LTM Mar 2026$23.06M -43.7%+6.3%7.2%
BLLNBillionToOne, Inc.LTM Jun 2026$12.18M ——3.1%
PSNLPersonalis, Inc.LTM Mar 2026$5.19M +29.3%-55.1%8.0%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding FLGT) $27.09M+39.2%-9.5%4.6%

Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income506.24M141.92M(175.24M)(43.82M)(61.63M)
Depreciation & Amortization11M32.66M26.14M24.93M24.12M
Deferred Income Tax(7.84M)831K7.61M(5.15M)(1.21M)
Stock-Based Compensation15.88M32.64M42.92M44.48M39.58M
Change in Working Capital(2.68M)2.01M2.84M(7.24M)(117.63M)
Accounts Receivables42.3M68.64M2.39M(16.3M)(23.25M)
Inventory00000
Accounts Payables(12.21M)(25.34M)(6.9M)3.07M550K
Other Working Capital(32.77M)(41.29M)7.35M6M(94.93M)
Other Non-Cash Items15.97M43.46M122.73M7.86M15.14M
Operating Cash Flow538.58M253.52M27M21.06M(101.64M)
Capital Expenditures(23.84M)(18.78M)(22.21M)(40.32M)(22.57M)
Acquisitions (Net)(61.87M)(182.68M)(399K)03.78M
Purchases of Investments(730.49M)(432.98M)(491.91M)(472.42M)(80.84M)
Sales of Investments269.59M372.71M552.64M454.07M211.01M
Other Investing Activities31K412K775K313K5K
Investing Cash Flow(546.55M)(261.31M)38.9M(58.35M)111.37M
Debt Repayment(11K)(1.07M)(20M)(1.77M)(870K)
Common Stock Issued89.48M0001K
Common Stock Repurchased(4.16M)(76.11M)(27.79M)(3.12M)(13.92M)
Dividends Paid00000
Other Financing Activities96K31K3K51K0
Financing Cash Flow85.41M(77.14M)(47.79M)(4.85M)(14.79M)
Effect of Forex Changes34K(453K)(149K)(55K)105K
Net Change in Cash77.47M(85.39M)17.97M(42.19M)(4.95M)
Free Cash Flow514.73M234.75M4.8M(19.26M)(124.21M)

Fulgent Genetics, Inc.

NASDAQ:FLGT

Intrinsic Alpha fair value

Locked

Current Price

$25.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.